In Women's Health, Hologic Stays Ahead of the Curve
Executive Summary
Hologic is garnering more attention these days than it might have in the past because it's just come off an "annus mirabilis." In 2006, Hologic made three vertical acquisitions in the area of breast cancer detection, and it reported stellar financial results. The company is now a market leader in osteoporosis assessment and has an approxmately 50% share of the conventional mammography customer base as well as an early lead in digital mammgoraphy, which is remarkable considering that it is a mid-sized company competing in capital equipment markets against the likes of GE and Siemens.
You may also be interested in...
Trends for the New Year: Can Medtech Build on the Success of 2007?
Looking back at 2007, the performance of the medical industry seems strong, from blockbuster M&A to a better-than-expected result of a years-long DOJ investigation into the orthopedics industry. Even Boston Scientific seemed finally to be turning the corner. Drug-eluting stents (DES) got a second chance as data presented from several trials showed better mortality than with bare-metal stents. Venture capitalists poured even more money into device start-ups, both young and old. The confidence shown by venture investors was, not surprisingly, reflected in an IPO market that appeared to continue its recent rebound. But there are also some concerns: company consolidation, increased safety concerns and litigation revolving around physician-manufacturer relationships are causing some to wonder how long the foundation on which the industry's strong showing of recent years can sustain.
Medical Device and In Vitro Diagnostics Deal Statistics Quarterly, Q2 2007
In this issue, we present another installment of our quarterly review of medical device and in vitro diagnostics/research dealmaking-for April-June 2007. Our data are derived from Windhover's Strategic Transactions Database.
Medical Device and In Vitro Diagnostics Deal Statistics Quarterly, Q2 2007
In this issue, we present another installment of our quarterly review of medical device and in vitro diagnostics/research dealmaking-for April-June 2007. Our data are derived from Windhover's Strategic Transactions Database.